Cajal Neuroscience

aid: cajal-neuroscience
name: Cajal Neuroscience
description: 'Cajal Neuroscience, which now operates publicly as Cajal Therapeutics, is a Seattle, Washington biotechnology
  company founded in 2020 by Alex Vaughan, Andrew Dervan and Ian Peikon, and launched in November 2022 with a $96 million
  Series A led by The Column Group and Lux Capital with participation from Two Sigma Ventures and Bristol Myers Squibb. The
  company develops small-molecule and RNA medicines that restore iron homeostasis, built around "iron mobilizers" — small
  molecules that transport iron across membranes into the compartments where it is required, bypassing disease-driven bottlenecks
  such as chronic inflammation, altered iron transporter expression and lysosomal dysfunction. Its pipeline spans systemic
  disease (CTX001, a clinical-stage iron mobilizer for anemia of chronic kidney disease; CTX201 and CTX211, preclinical siRNA
  programs for inflammatory anemia and myelofibrosis anemia) and CNS disease (a discovery-stage brain-penetrant iron mobilizer
  for Parkinson''s disease). This is a therapeutics company, not a software or data platform company: it publishes no developer
  program, no public API, and no machine-readable API contract. Its public GitHub organization contains open-source laboratory
  hardware and firmware (a drone-motor spin coater, a microfluidic pressure sensor, a flow sensor) plus forks of third-party
  single-cell and genomics analysis tooling — none of which expose a network API.'
url: https://raw.githubusercontent.com/api-evangelist/cajal-neuroscience/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: no-api-surface
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://www.cajal-tx.com/apple-touch-icon.png
specificationVersion: '0.23'
created: '2026-08-08'
modified: '2026-08-08'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Neurodegeneration
- Neuroscience
- Therapeutics
- Life Sciences
- Genomics
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/cajal-neuroscience-domain-security.yml
- type: Website
  url: https://www.cajal-tx.com/
- type: GitHubOrganization
  url: https://github.com/CajalNeuroscience
- type: PrivacyPolicy
  url: https://www.cajal-tx.com/privacy
- type: News
  url: https://www.cajal-tx.com/news
- type: Contact
  url: https://www.cajal-tx.com/contact
- type: Careers
  url: https://www.cajal-tx.com/careers
- type: LinkedIn
  url: https://www.linkedin.com/company/cajal-tx/
- type: LLMsTxt
  url: llms/cajal-neuroscience-llms.txt
x-enrichment:
  date: '2026-08-08'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Cajal is a clinical-stage iron-homeostasis therapeutics company (CTX001 in Phase 1) whose only public engineering
    output is open-source lab-bench hardware — a drone-motor spin coater and two microfluidic sensors — so there is no product
    for an API to expose; cajalneuro.com 307-redirects to cajal-tx.com, and api./docs./developer./data.cajal-tx.com have no
    DNS record at all.
  evidence:
  - url: https://www.cajal-tx.com/openapi.json
    status: 404
  - url: https://www.cajal-tx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.cajal-tx.com/.well-known/api-catalog
    status: 404
  - url: https://www.cajal-tx.com/llms.txt
    status: 404
  - url: https://api.github.com/orgs/CajalNeuroscience
    status: 200
  checked: '2026-08-08'